Bortezomib-based treatment of antibody mediated rejection in pancreas allograft recipients.
This report presents the first experience with plasma cell-targeted therapy in treating antibody mediated rejection in pancreas transplant recipients. In this experience, bortezomib provided results similar to those previously reported in kidney transplant recipients, with the exception that DSA responses were not quite as dramatic in pancreas transplant recipients. However, even in patients with antibody mediated rejection refractory to standard therapies, significant responses were obtained with the proteasome inhibitor, bortezomib. These results confirm the potential for bortezomib-based therapies in pancreas transplant recipients, and also demonstrate that rejection following pancreas transplantation may require innovative approaches to provide optimal results.
The University of Cincinnati Medical Center, Cincinnati, Ohio, USA.
Amit
A
Govil
R Carlin
RC
Walsh
Amit
A
Tevar
Rita
R
Alloway
Prabir
P
Roy-Chaudhury
Gautham
G
Mogilishetty
Garth E
GE
Wall
Paul
P
Brailey
Alin
A
Girnita
E Steve
ES
Woodle
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001706:Biopsy; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D003404:Creatinine / Q000097:blood; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy; D006801:Humans; D007518:Isoantibodies / Q000097:blood* / Q000187:drug effects; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D016035:Pancreas Transplantation / Q000276:immunology*; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011719:Pyrazines / Q000627:therapeutic use*; D014184:Transplantation, Homologous / Q000473:pathology; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001897:Boronic Acids; D007518:Isoantibodies; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib; D003404:Creatinine